Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
Norwegian Diabetes Register for Adults, Norwegian Organization for Quality Improvement of Laboratory Examinations (Noklus), Haraldsplass Deaconess Hospital, Bergen, Norway.
Diabet Med. 2024 Jul;41(7):e15335. doi: 10.1111/dme.15335. Epub 2024 Apr 25.
To describe trends in risk factor control and serious hypoglycaemia in people with type 1 diabetes and to assess the effect of starting continuous glucose monitoring (CGM) in the real-world setting.
Two cross-sectional surveys including 5746 individuals in 2012 and 18,984 individuals in 2020 based on data recorded in the Norwegian Diabetes Register for Adults (NDR-A) and an analysis of a longitudinal cohort of 2057 individuals where data on CGM and HbA1c were available in the NDR-A in 2012 and 2020.
In the cross-sectional surveys mean HbA1c decreased from 66 mmol/mol (99% CI 65, 66) (8.2%) in 2012 to 61 mmol/mol (99% CI 61, 61) (7.7%) in 2020 (p < 0.0001). The proportion reporting serious hypoglycaemia decreased from 16.9 to 6.2% in 2020 (p < 0.0001). Mean LDL-cholesterol decreased from 2.80 (99% CI 2.78, 2.83) to 2.63 (99% CI 2.61, 2.65) mmol/l in 2020 (p < 0.0001). Mean blood pressure increased slightly. In the CGM cohort, we found a 3 mmol/mol (0.3%) greater improvement in mean HbA1c and a greater reduction in serious hypoglycaemia (-12.3% vs. -6.2%) among individuals that had started using CGM between 2013 and 2020 when compared with individuals that had not started using CGM.
Between 2012 and 2020, we found marked improvements in glycaemic control and a considerable decrease in the proportion of individuals reporting serious hypoglycaemia. The proportion of individuals using CGM increased substantially and individuals that had started using CGM by 2020 showed greater improvement in glycaemic control and less serious hypoglycaemia.
描述 1 型糖尿病患者的危险因素控制和严重低血糖趋势,并评估在真实环境中开始连续血糖监测(CGM)的效果。
基于成人挪威糖尿病登记处(NDR-A)中记录的数据,进行了两项横断面调查,共纳入 2012 年的 5746 人和 2020 年的 18984 人,同时对 2057 名个体的纵向队列进行了分析,这些个体在 2012 年和 2020 年的 NDR-A 中均有 CGM 和 HbA1c 数据。
在横断面调查中,2012 年的平均 HbA1c 从 66mmol/mol(99%CI 65,66)(8.2%)降至 2020 年的 61mmol/mol(99%CI 61,61)(7.7%)(p<0.0001)。2020 年报告严重低血糖的比例从 16.9%降至 6.2%(p<0.0001)。2020 年 LDL-胆固醇均值从 2.80(99%CI 2.78,2.83)mmol/L降至 2.63(99%CI 2.61,2.65)mmol/L(p<0.0001)。平均血压略有升高。在 CGM 队列中,与未开始使用 CGM 的个体相比,2013 年至 2020 年期间开始使用 CGM 的个体,平均 HbA1c 改善了 3mmol/mol(0.3%),严重低血糖的发生率降低了 12.3%(-12.3%比-6.2%)。
2012 年至 2020 年间,我们发现血糖控制明显改善,报告严重低血糖的个体比例显著下降。使用 CGM 的个体比例大幅增加,2020 年开始使用 CGM 的个体血糖控制改善更大,严重低血糖发生更少。